(Q41044551)

English

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

scientific article published on 15 April 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 September 2017

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials (English)

1 reference

Europe PubMed Central

26 September 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Daniel Podzamczer

9

object named as

Daniel Podzamczer

1 reference

Europe PubMed Central

26 September 2017

1

object named as

Paul E Sax

1 reference

Europe PubMed Central

26 September 2017

6

object named as

Michael Saag

1 reference

Europe PubMed Central

26 September 2017

Jean-Michel Molina

10

object named as

Jean Michel Molina

1 reference

Europe PubMed Central

26 September 2017

Benoit Trottier

13

object named as

Benoit Trottier

1 reference

Europe PubMed Central

26 September 2017

Christian Callebaut

21

object named as

Christian Callebaut

1 reference

Europe PubMed Central

26 September 2017

author name string

David Wohl

2

1 reference

Europe PubMed Central

26 September 2017

Michael T Yin

3

1 reference

Europe PubMed Central

26 September 2017

Frank Post

4

1 reference

Europe PubMed Central

26 September 2017

Edwin DeJesus

5

1 reference

Europe PubMed Central

26 September 2017

Anton Pozniak

7

1 reference

Europe PubMed Central

26 September 2017

Melanie Thompson

8

1 reference

Europe PubMed Central

26 September 2017

Shinichi Oka

11

1 reference

Europe PubMed Central

26 September 2017

Ellen Koenig

12

1 reference

Europe PubMed Central

26 September 2017

Jaime Andrade-Villanueva

14

1 reference

Europe PubMed Central

26 September 2017

Gordon Crofoot

15

1 reference

Europe PubMed Central

26 September 2017

Joseph M Custodio

16

1 reference

Europe PubMed Central

26 September 2017

Andrew Plummer

17

1 reference

Europe PubMed Central

26 September 2017

Lijie Zhong

18

1 reference

Europe PubMed Central

26 September 2017

Huyen Cao

19

1 reference

Europe PubMed Central

26 September 2017

Hal Martin

20

1 reference

Europe PubMed Central

26 September 2017

Andrew K Cheng

22

1 reference

Europe PubMed Central

26 September 2017

Marshall W Fordyce

23

1 reference

Europe PubMed Central

26 September 2017

Scott McCallister

24

1 reference

Europe PubMed Central

26 September 2017

GS-US-292-0104/0111 Study Team

25

1 reference

Europe PubMed Central

26 September 2017

language of work or name

0 references

publication date

15 April 2015

1 reference

Europe PubMed Central

26 September 2017

1 reference

Europe PubMed Central

26 September 2017

385

1 reference

Europe PubMed Central

26 September 2017

9987

1 reference

Europe PubMed Central

26 September 2017

2606-2615

1 reference

Europe PubMed Central

26 September 2017

Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The fallback procedure for evaluating a single family of hypotheses.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of tenofovir exposure with kidney disease risk in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous antiretroviral therapy decreases bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A generalized least significant change for individuals measured on different DXA systems

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960616-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(15)60616-X

1 reference

Europe PubMed Central

26 September 2017

1 reference

Europe PubMed Central

26 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41044551&oldid=2120313128"